<SUBMISSION>
<ACCESSION-NUMBER>0001144204-03-005955
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20030930
<ITEMS>5
<ITEMS>7
<FILING-DATE>20031001
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED BIOTHERAPY INC
<CIK>0000791833
<ASSIGNED-SIC>8731
<IRS-NUMBER>510402415
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26323
<FILM-NUMBER>03918666
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
<PHONE>8188833956
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>ADVANCED BIOTHERAPY CONCEPTS INC
<DATE-CHANGED>19990524
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.txt
<TEXT>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest reported)           September 30, 2003
                                           ----------------------------------

                           Advanced Biotherapy, Inc.
             (Exact name of registrant as specified in its charter)

         Delaware                     0-26323              51-0402415
----------------------------     -------------------    ---------------------
(State or other jurisdiction         (Commission         (IRS Employer
             of incorporation)        File Number)       Identification No.)

6355 Topanga Canyon Boulevard, Suite 510                            91367
----------------------------------------                            -----
Woodland Hills, California                                       (Zip Code)
--------------------------
(Address of principal executive offices)

Registrant's telephone number, including area code   (818) 883-6716
                                                   --------------------





<PAGE>



Item 5.  OTHER EVENTS.

         The registrant, Advanced Biotherapy Inc. published a press release on
September 30, 2003, reporting the results of its sponsored investigational
clinical trial comparing two different investigational treatments known as
anticytokine therapy for patients suffering from rheumatoid arthritis.

Item 7.  FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits.

Designation    Description of Exhibit

99.1           Press Release, dated September 30, 2003


                                   Signatures

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                     ADVANCED BIOTHERAPY, INC.
                                     (Registrant)


Date September 30, 2003              By:  /s/Edmond Buccellato
                                        -------------------------------
                                        Edmond Buccellato, President and CEO




                                INDEX TO EXHIBITS

        Exhibit               Description
        -------               -----------

        99.1                  Text of Press Release, dated September 30, 2003






</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex-99_1.txt
<TEXT>
 EXHIBIT 99.1


                               ADVANCED BIOTHERAPY, INC.
                                     6355 Topanga Canyon Boulevard, Suite 510
                                     Woodland Hills, California  91367
                                     Telephone 818-883-6716
                                     Fax           818-883-3353
                                     www.advancedbiotherapy.com

                             "FOR IMMEDIATE RELEASE"

    Advanced Biotherapy Inc. Reports on Investigational Clinical Studies in
                              Rheumatoid Arthritis

  Beneficial Effects of Antibodies to Interferon-Gamma Presented at Conference

LOS  ANGELES--(BUSINESS  WIRE)--September  30, 2003--  Advanced  Biotherapy Inc.
(OTCBB:ADVB - News) - a developer of pioneering  antibody therapies for treating
severe  and  widespread  autoimmune  diseases  -  reported  the  results  of its
sponsored investigational clinical trial comparing two different investigational
treatments known as anticytokine  therapy for patients suffering from rheumatoid
arthritis  at the  International  Cytokine  Society  Annual  Meeting  in Dublin,
Ireland,  last  week.  Results  of  this  investigational  study  confirmed  the
beneficial effects of using antibodies to block interferon-gamma to treat severe
rheumatoid arthritis.

         Mr. Edmond  Buccellato,  the Company's CEO,  explained,  "As previously
reported,  and as we were pleased to report at this annual meeting,  the Company
sponsored an investigational randomized,  double-blind trial in 55 patients with
severe rheumatoid  arthritis  unresponsive to other  anti-arthritic  treatments.
This  trial  follows  a  preliminary  study  with  25  patients  which  produced
encouraging  results. The 55 patients were given a short course of antibodies to
interferon-gamma,  a short course of antibodies to tumor necrosis  factor-alpha,
or  a  placebo.  Four  weeks  after  treatment,  both  the  group  receiving  an
investigational   antibody  to  interferon-gamma  and  the  group  receiving  an
investigational  antibody to tumor  necrosis  factor-alpha  exhibited  sustained
significant  improvement  in all  clinical  measures.  However,  analysis  using
ultrasound  measurement of the thickness of the inflamed  knee-joint lining (the
synovial  membrane)  established that only  anti-interferon-gamma  resulted in a
significant reduction in membrane thickness in patients. Also at four weeks from
the initiation of treatment,  using criteria for measuring therapeutic responses
established  by the  American  College of  Rheumatology,  the number of patients
achieving  the maximum level of response was found to be greater in the patients
receiving   antibody  to   interferon-gamma.   This  randomized,   double-blind,
placebo-controlled investigational trial was performed in Moscow, Russia, by the
Director of the  Rheumatology  Clinic,  Professor Yakov Sigidin,  and Dr. Galina
Lukina  at  the  Rheumatology  Institute  of the  National  Academy  of  Medical
Sciences."

         Mr.  Buccellato  concluded  by stating "It is our  undaunted  view that
treating certain autoimmune  diseases with antibodies to  interferon-gamma  is a
sound and  scientifically  rational approach - an opinion supported by others in
the scientific community."

The Company's  approach to the  treatment of autoimmune  disease is based on the
pioneering  hypothesis  published  in  the  journal  Nature  in  1974  by  Simon
Skurkovich,  M.D., the Company's  Director of Research and Development,  stating

<PAGE>

that a disturbance  in the  production of  interferon,  a cytokine,  can lead to
autoimmune  disease and that blocking this substance  could be  therapeutic.  In
1989 Dr.  Skurkovich  further  hypothesized  that  antibodies to tumor  necrosis
factor-alpha,  a cytokine induced by interferon-gamma,  could be a useful method
of  treatment  for  autoimmune  diseases.  At  present,  the  only  anticytokine
therapies  available  commercially to treat rheumatoid  arthritis are drugs that
block tumor necrosis factor-alpha.

Rheumatoid arthritis is a chronic condition characterized by inflammation in the
lining of the joints which can eventually bring damage to bone and cartilage. In
the U.S. alone, more than three million people suffer from rheumatoid arthritis.

Autoimmune  diseases  in  general  are the  result  of an  inappropriate  immune
response in which the body's  immune  system  attacks its own healthy  cells and
organs.   In  these   disorders,   certain   chemicals   called   cytokines  are
hyperproduced,  and bring about the autoimmune  condition.  One of the company's
patented therapies is designed to remove or neutralize these excessive cytokines
known as interferon-gamma and tumor necrosis  factor-alpha,  which is induced by
interferon-gamma.   Removal  of  these  agents  is  associated  with  beneficial
therapeutic  effects and could possibly form the basis of a universal  treatment
for  certain  types of  autoimmune  diseases.  Advanced  Biotherapy  has already
achieved  encouraging results in clinical trials in multiple  sclerosis,  type I
diabetes,   various  autoimmune  skin  diseases  (psoriasis,   alopecia  areata,
vitiligo, pemphigus, and epidermolysis bullosa), uveitis, and corneal transplant
rejection.

About Advanced Biotherapy
Advanced  Biotherapy,  Inc.  is  pioneering  the  development  of  new  antibody
therapies  for  treating  severe  and  widespread   autoimmune   diseases.   Its
investigational   therapies   attack   autoimmune   diseases  at  their  source,
neutralizing  biologic  imbalances  that impair  immune  system  function.  Core
technology is protected under U.S. patents and patents pending for the exclusive
use of a class of  antibodies to the protein  known as  interferon-gamma  and to
tumor  necrosis  factor-alpha  for treating a range of diseases.  The company is
headquartered in Los Angeles, California. www.advancedbiotherapy.com.

Statements made in this news release,  other than statements of historical fact,
are forward-looking statements and are subject to a number of uncertainties that
could cause actual results to differ materially from the anticipated  results or
other expectations  expressed in our forward-looking  statements.  The risks and
uncertainties  which may affect the  development,  operations and results of our
business  include,  but are not limited to the following:  risks associated with
clinical trials, the uncertainties of research and product development programs,
the  uncertainties  of obtaining  regulatory  approval to conduct United States'
based clinical trials, the uncertainties of the regulatory approval process, the
risks of competitive products,  the risks of our current capital resources,  the
uncertainties  as to the  availability  of future capital and our future capital
requirements,  and the risks  associated  with the  extent  and  breadth  of the
Company's   patent   portfolio.   The  foregoing   discussion  of  the  clinical
investigations  and the effect of the patents issued and pending  involves risks
and uncertainties, including but not limited to the risks that third parties may
be successful in  challenging  such patents;  or that granted claims may be held
invalid or interpreted  differently by a court of law; or that new  technologies
will be  developed  that are  superior  in  treating  the  diseases  targeted by
Advanced  Biotherapy,  Inc. Readers are cautioned not to place reliance on these
forward-looking statements,  which speak only as of the date the statements were
made.  See the  Company's  public  filings  with  the  Securities  and  Exchange
Commission for further information about risks and uncertainties that may affect
the Company and the results or  expectations  expressed  in our  forward-looking
statements,  including  the  section  captioned  "Factors  That May  Affect  The
Company"  contained  in the  Company's  Annual  Report on Form  10-KSB/A for the
fiscal year ended December 31, 2002.

-----------------
Contact:
     Advanced Biotherapy, Inc.
     Amy Buccellato, 818-883-6716
     www.advancedbiotherapy.com
     --------------------------




</TEXT>
</DOCUMENT>
</SUBMISSION>
